Klin Farmakol Farm. 2009;23(2):53-57

Risky combinations of cardiovascular drugs in elderly patients and factors increasing the probability of their occurrence

Martin Wawruch
Farmakologický ústav Lekárskej fakulty UK, Bratislava

Aim: The aim of the presented work was to analyse the prevalence of risky combinations of cardiovascular drugs. We assessed also patients

´ characteristics that increase the probability of their occurrence.

Methods: We enrolled 600 patients aged 65 years or more admitted to the Department of Internal Medicine of the Hospital in Povazska

Bystrica. To identify risky combinations of cardiovascular drugs the study of Vlahović-Palčevski et Bergman was applied. To define the

most important patient’s characteristics associated with the occurrence of risky combinations of cardiovascular medications, the binary

logistic regression model (SPSS for Windows, 15th version) was used.

Results: Risky combinations of cardiovascular drugs according to Vlahović-Palčevski and Bergman were found in 47 patients (7.8 %). The

combinations of angiotensin-converting enzyme (ACE) inhibitors with potassium sparing diuretics or with potassium supplements were

found to be the most common. Polypharmacy (odds ratio (OR) = 2.38; 95% confidence interval (CI) = 1.50–3.79), immobilization (OR =

1.87; 95% CI = 1.16–3.00) and atrial fibrillation (OR = 1.73; 95% CI = 1.13–2.64) were considered the most important patient’s characteristics

associated with prescription of risky combinations.

Conclusion: Elderly persons represent a vulnerable group regarding drug-drug interactions because of the common presence of polymorbidity

and polypharmacy. Present study is one of the studies that provide information on prescription of risky combinations of

cardiovascular drugs in elderly patients. The significant proportion of risky combinations observed in present study may be considered

rationally prescribed when laboratory markers and patients status is regularly monitored. Implementation of this topic within the framework

of continual medical education is needed.

Keywords: drug-drug interactions, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs, warfarin, diuretics.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wawruch M. Risky combinations of cardiovascular drugs in elderly patients and factors increasing the probability of their occurrence. Klin Farmakol Farm. 2009;23(2):53-57.
Download citation

References

  1. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54. Go to original source... Go to PubMed...
  2. Bartošovič I, Krajčík Š, Hegyi L. Farmakoterapia v zariadeniach sociálnych služieb pre starých ľudí. Praktický lékař 2003; 83: 340-343.
  3. Wawruch M, Zikavska M, Wsolova L, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharm World Sci 2008; 30: 235-242. Go to original source... Go to PubMed...
  4. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003; 78: 1564-1577. Go to original source... Go to PubMed...
  5. Hegyi L. Compliance vo vyššom veku. Geriatria 2005; 11: 78-82.
  6. ICD - 10th International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva: WHO, 1992: 191.
  7. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboomde Jong B. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17: 261-267. Go to original source... Go to PubMed...
  8. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980; 9: 73-80. Go to original source... Go to PubMed...
  9. Vlahović-Palcevski V, Bergman U. Quality of prescribing for the elderly in Croatia-computerized pharmacy data can be used to screen for potentially inappropriate prescribing. Eur J Clin Pharmacol 2004; 60: 217-220. Go to original source... Go to PubMed...
  10. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). Eur Heart J 2005; 26: 1115-1140. Go to original source... Go to PubMed...
  11. Wayne DW. Biostatistics: A foundation for analysis in the health sciences. 7th ed. Chichester: Wiley, 1999: 557.
  12. Magulová L, Božeková L, Kriška M, eds. Interakcie liečiv v klinickej praxi. 2. vyd. Bratislava: Slovak Academic Press, 2004: 333.
  13. Tatro DS. Drug interaction facts. 3rd ed. St. Louis: Facts and Comparisons, 1999: 1295.
  14. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592. Go to original source... Go to PubMed...
  15. Hradec J. Farmakoterapie v kardiologii. In: Marek J, eds. Farmakoterapie vnitřních nemocí. 3. vyd. Praha: Grada Publishing, 2005: 25-62.
  16. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-740. Go to original source... Go to PubMed...
  17. Beyth RJ, Landefeld CS. Anticoagulants in older patients. A safety perspective. Drugs Aging 1995; 6: 45-54. Go to original source... Go to PubMed...
  18. Urbánek K, Kohlová I, Ürge J, Marečková J. Informovanost, percepce rizik a compliance pacientů užívajícich warfarin. Klin Farmakol Farm 2008; 22: 6-10.
  19. Kriška M, eds. Riziko liekov v medicínskej praxi. Bratislava: Slovak Academic Press, 2000: 474.
  20. Go A, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934. Go to original source... Go to PubMed...
  21. Chatap G, Giraud K, Vincent JP. Atrial Fibrillation in the elderly: Facts and management. Drugs Aging 2002; 19: 819-846. Go to original source... Go to PubMed...
  22. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione EmiliaRomagna, Italy. J Clin Pharm Ther 2008; 33: 141-151. Go to original source... Go to PubMed...
  23. Zhan C, Correa-de-Araujo R, Bierman AS et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 2005; 53: 262-267. Go to original source... Go to PubMed...
  24. Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293: 1348-1358. Go to original source... Go to PubMed...
  25. Bjerrum L, Gonzalez Lopez-Valcarcel B, Petersen G. Risk factors for potential drug interactions in general practice. Eur J Gen Pract 2008; 14: 23-29. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.